Circulating Tumor Cell Composition in Renal Cell Carcinoma

Nel, Ivonne; Gauler, Thomas; Bublitz, Kira; Lazaridis, Lazaros; Goergens, André; Giebel, Bernd; Schüler, Martin; Hoffmann, Andreas-Claudius

doi:10.1371/journal.pone.0153018

Cited by 41 publications

(36 citation statements)

References 45 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through the studies for metabolomics, many promising candidates of a biomarker for RCC that were useful not only for early detection, but also the prediction of the effects of therapeutic agents and prognosis, have been identified. 115 Consistent with other malignant diseases, upregulation of aerobic glycolysis and the increase of some metabolites related to glycolysis, such as glucose, pyruvate and lactate, are shown in RCC patients. 116 In contrast, downregulation of the tricarboxylic acid cycle, an increase of citrate and succinate, and a decrease of fumarate and malate have been reported.…”

Section: Ctcssupporting

confidence: 58%

“…In oncological research, metabolomics approaches have been focused, and metabolomics reprogramming has been recognized as a crucial point of cancer biology. Through the studies for metabolomics, many promising candidates of a biomarker for RCC that were useful not only for early detection, but also the prediction of the effects of therapeutic agents and prognosis, have been identified …”

Section: Other Candidates Of Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Current status of prognostic factors in patients with metastatic renal cell carcinoma

et al. 2019

View full text Add to dashboard Cite

In recent years, the induction of novel agents, including molecular‐targeted agents and immune checkpoint inhibitors, have dramatically changed therapeutic options and their outcomes for metastatic renal cell carcinoma. Several prognostic models based on the data of patients with metastatic renal cell carcinoma treated with targeted agents or cytokine therapy have been useful in real clinical practice. Serum or peripheral blood markers related to inflammatory response have been reported to be associated with their prognosis or therapeutic efficacy. In addition to them, investigation for novel predictive factors that represent the efficacy of agents, the risk of adverse events and the prognosis are required for the advance of therapeutic strategies. The present review discusses the conventional prognostic models and clinical factors, and recent advances of the identification of some of the most promising molecules as novel biomarkers for metastatic renal cell carcinoma.

show abstract

Section: Ctcssupporting

confidence: 58%

Section: Other Candidates Of Biomarkersmentioning

confidence: 99%

Current status of prognostic factors in patients with metastatic renal cell carcinoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…While several studies report detection and characterization of CTCs in tumor entities including breast or prostate cancer, the number of reports describing CTC detection in clear cell renal cell carcinoma (ccRCC) patients is limited. Most initial studies describe whole blood nucleic acid extraction and analysis [ 11 – 16 ] or CD45-negative selection [ 6 , 14 – 16 ]. In a comparison of different tumor entities using the CellSearch system, ccRCC showed the lowest frequency of CTCs compared to all other tumor entities [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Comparison of isolation platforms for detection of circulating renal cell carcinoma cells

Maertens

Humberg

Erlmeier³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

BackgroundAnalysis of circulating tumor cells (CTCs) has progressed in several tumor entities. However, little is known about CTCs in clear cell renal cell carcinoma (ccRCC) patients. Aim of our studies was to build a stable in vitro fundament for isolation of CTCs in ccRCC.MethodsWe compared the analytical performance of different CTC isolation methods with regard to yield and purity: EpCAM based enrichment, leukocyte depletion and size based enrichment. EpCAM and cytokeratin 8 (KRT8) as biomarker for CTCs expression were evaluated in ccRCC cell lines as well as clinical samples.ResultsWhile the EpCAM based approach failed to successfully isolate tumor cells, CD45 based approaches showed intermediate recovery rates. The cell-size based Parsortix system showed highest recovery rates. EpCAM expression was low or absent in most cell lines as well as in clinical samples, whereas KRT8 was detected as a potential biomarker in ccRCC.ConclusionEpCAM based approaches might miss a high number of CTCs due to low or absent expression of EpCAM in ccRCC, as shown in cell lines as well as in patient samples. We identified the cell-sized based, label independent Parsortix system to be the most effective recovery system for ccRCC CTCs.

show abstract

“…Bluemke discovered that positive CK+ CTCs was significantly correlated with inferior overall survival for renal cancer patients [13]. Nel found that the presence and quantity of CD133-positive or N-cadherin-positive CTC was associated with poor PFS in 14 renal cancer patients [27]. Due to the relative short follow-up time and relative early stage of patients, 15.3% patients (20/131) experienced recurrence or metastasis in our study.…”

Section: Discussionmentioning

confidence: 54%

Perioperative circulating tumor cells (CTCs) and CTC-white blood cells detected by a size-based platform predict worse prognosis in renal cell cancer patients

Wang¹,

Zhang²,

Chong³

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose To explore the clinical significance of perioperative CTCs counts, EMT-CTCs and CTC- white blood cells (WBCs) in renal cancer patients.Materials and Methods A total of 131 patients with renal cancer who underwent operation from the Second Affiliated Hospital of Xi’an Jiaotong University were enrolled. 20 patients with benign renal diseases were used as control. 5 mL Peripheral blood was extracted from 131 patients with renal cancer before operation and about 3 months after operation. Control patients took blood at the corresponding time. CanPatrol CTC detection technique was used to enrich and identify CTCs, EMT-CTCs and CTC-WBCs simultaneously.Results All patients enrolled were T1-3N0M0. 52 renal cancer patients received radical resection, while other 79 patients underwent nephron-sparing surgery. The positive rate of CTC, mesenchymal CTCs (MCTC) and CTC-WBC before surgery were 95.4% (125/131), 61.1% (80/131) and 11.5% (15/131), respectively. Preoperative total CTCs, mesenchymal CTCs or CTC-WBCs were poorly correlated with patients’ parameters. Preoperative CTC, MCTC or CTC-WBC showed little association with progression-free survival (PFS), while post-operation total CTC (≥ 6), positive mesenchymal CTCs and positive CTC-WBC significantly correlated with early recurrence and metastasis, and remained independent indicators for worse PFS. In addition, the elevation of CTC and MCTC after operation were also correlated with unfavourable PFS.Conclusions With the detection of CTCs in peripheral blood, better risk stratification of renal cancer patients might therefore help to identify a subset of patients that might have higher recurrent risk than the overall population of patients.

show abstract

Circulating Tumor Cell Composition in Renal Cell Carcinoma

Cited by 41 publications

References 45 publications

Current status of prognostic factors in patients with metastatic renal cell carcinoma

Current status of prognostic factors in patients with metastatic renal cell carcinoma

Comparison of isolation platforms for detection of circulating renal cell carcinoma cells

Perioperative circulating tumor cells (CTCs) and CTC-white blood cells detected by a size-based platform predict worse prognosis in renal cell cancer patients

Contact Info

Product

Resources

About